Status: Recruiting
A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
A randomized, double-blind, placebo-controlled design was designed to evaluate the safety and tolerability, pharmacokinetic/pharmacodynamic profile, and immunogenicity of multiple administration of STSA-1301 subcutaneous injection in healthy subjects and patients with ITP, and to further explore the initial efficacy of STSA-1301 subcutaneous injection in patients with ITP
Participants needed: 56
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Jiangsu BioJeTay Biotechnology Co., Ltd.Updated: Aug 12, 2026Locations: 7
Eligibility criteria
18 years ≤ age ≤ 50 years, male or female subjects; [+12]
Subject has a history of serious medical conditions (including, but not limited... [+37]